1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Aneurysm characteristics, treatment complications, and morbidity and mortality in patients treated with WEB DL and WEB SL (and SLS)
WEB DL WEB SL/SLS P Value
Patients 30 32 
    Age (mean) (yr) 55.6 ± 8.9 57.4 ± 10.3 .86
    Female 24/30 (80.0%) 16/32 (50.0%) .20
Aneurysms 31 32 
    Ruptured 2/31 (6.5%) 5/32 (15.6%) .42
    AcomA 4/31 (12.9%) 12/32 (37.5%) .04
    Aneurysm <10 mm 21/31 (67.7%) 31/32 (96.9%) .002
    Neck >4 mm 29/31 (96.5%) 28/32 (87.5%) .67
Antiplatelet treatment^{^a} 
    Before treatment 4/30 (13.3%) 11/32 (34.4%) .07
    During treatment 22/30 (73.3%) 20/32 (62.5%) .42
    After treatment 26/30 (86.7%) 22/32 (68.8%) .13
Treatment feasibility 30/31 (96.8%) 32/32 (100.0%) .49
Adjunctive treatment 4/30 (13.3%) 3/32 (9.4%) .70
Adverse events 
    Device problems 3/30 (10.0%) 2/32 (6.3%) .66
    TE^{^b} 7/30 (23.3%) 3/32 (9.4%) .17
    IOR 1/30 (3.3%) 0/32 (0.0%) .48
Morbidity/mortality 
    Morbidity 1/30 (3.3%) 1/32 (3.1%) 1
    Mortality 0/30 (0.0%) 0/32 (0.0%) 1
Note:—TE indicates thromboembolic event/appearance of thrombus; IOR, intraoperative rupture.
↵a One or 2 medications.
↵b DL group: no clinical deficit in 3, transient deficits in 3, permanent deficit in 1. SL group: no deficit in 1, transient deficits in 2.